A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

被引：2
|
作者：
Andre, F. [1 ]
Kaufman, B. [2 ]
Juric, D. [3 ]
Ciruelos, E. [4 ]
Iwata, H. [5 ]
Mayer, I. A. [6 ]
Conte, P. [7 ]
Rugo, H. S. [8 ]
Loibl, S. [9 ]
Rubovszky, G. [10 ,11 ]
Tesch, H. [12 ]
Inoue, K. [13 ]
Lu, Y-S. [14 ]
Ryvo, L. [15 ]
Longin, A-S. [16 ]
Mills, D. [16 ,17 ]
Wilke, C. [17 ]
Germa, C. [18 ]
Campone, M. [19 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France
[2] Chaim Sheba Med Ctr, Breast Canc Unit, Ramat Gan, Israel
[3] Massachusetts Gen Hosp, Termeer Ctr Targeted Therapies, Boston, MA 02114 USA
[4] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[5] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[6] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[7] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy
[8] Univ Calif San Francisco, Ctr Comprehens Canc, Med Hematol Oncol, San Francisco, CA 94143 USA
[9] German Breast Grp, Med & Res, Neu Isenburg, Germany
[10] Natl Inst Oncol, Internal Med Oncol Div B, Budapest, Hungary
[11] Natl Inst Oncol, Dept Clin Pharmacol, Budapest, Hungary
[12] Ctr Hamatol & Onkol Bethanien, Dept Oncol, Frankfurt, Germany
[13] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Tel Aviv Sourasky Med Ctr Ichilov, Div Oncol, Tel Aviv, Israel
[16] Novartis Pharma SAS, Paris, France
[17] Novartis Pharma AG, Basel, Switzerland
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Ctr Rene Gauducheau, Med Oncol, Inst Cancerol Ouest Site, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen
    Fasching, Peter A.
    De Laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Val
    Esteva, Francisco J.
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    De la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Karen Rodriguez
    Miller, Michelle
    Taran, Tetiana
    Jerusalem, Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2465 - +
  • [22] Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
    Garcia-Saenz, Jose A.
    Martinez-Janez, Noelia
    Cubedo, Ricardo
    Jerez, Yolanda
    Lahuerta, Ainhara
    Gonzalez-Santiago, Santiago
    Ferrer, Nieves
    Ramos, Manuel
    Alonso-Romero, Jose L.
    Anton, Antonio
    Carrasco, Eva
    Chen, Jingjing
    Neuwirth, Rachel
    Galinsky, Kevin
    Vincent, Sylvie
    Leonard, E. Jane
    Slamon, Dennis
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1107 - 1116
  • [23] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Khanzada, Mikail
    Zaheer, Zaofashan
    Fatima, Eeshal
    Bakhtiar, Muhammad
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [24] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
    De Laurentiis, Michelino
    Costa, Luis
    Gligorov, Joseph
    Knop, Ann
    Senkus-Konefka, Elzbieta
    Garcia-Saenz, Jose A.
    Schmid, Peter
    Heniquez, Aurelia
    Serra, Paolo
    Reising, Albert
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Sellami, Dalila
    El-Hashimy, Mona
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    Baselga, Jose
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S.
    Petrakova, K.
    Bianchi, G. Valeria
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Ji, Y.
    Wang, C.
    Deore, U.
    Chakravartty, A.
    Zarate, J. P.
    Taran, T.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1015 - 1024
  • [27] Patterns of disease management for European postmenopausal women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer
    Marinsek, N.
    Andre, F.
    Neven, P.
    Zhang, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S411 - S411
  • [28] COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R plus F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S45 - S45
  • [29] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [30] Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial
    Hong, Ruo-Xi
    Xu, Fei
    Xia, Wen
    Teng, Yue-E
    Ouyang, Qu-Chang
    Zheng, Qiu-Fan
    Yuan, Zhong-Yu
    Chen, Dong-Shao
    Jiang, Kui-Kui
    Lin, Ying
    Dai, Zhen
    Liu, Xin-Lan
    Chen, Qian-Jun
    Wu, Xin-Hong
    Shi, Yan-Xia
    Huang, Jia-Jia
    An, Xin
    Xue, Cong
    Bi, Xi-Wen
    Chen, Mei-Ting
    Li, Hui
    Yao, He-Rui
    Zou, Guo-Rong
    Huang, Heng
    Zhang, Jing-Min
    Wang, Shu-Sen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
12345